SIRONA BIOCHEM WKN: A0RM6R ISIN: CA82967M1005 Kürzel: ZSB Forum: Aktien Thema: Hauptdiskussion

Post wurde gelöscht.

Post wurde gelöscht.

Daher !

Turn-around Interesting week that provided the long awaited turn-around of the company - and the share price.  The non-disclosure of AbbVie deal details was painful and I noted that investors gave up and choose to sell. I don't blame them. Was the terms fantastic or in line with R+F to get street cred? Frustrating to say the least. The brief prc Partners analysis provided breadcrumbs that ignited some hope since they obviously know a bit more than other investors at this stage. The interview seems to be ready before the AbbVie deal was announced. The analyst claimed that AbbVie had already started product development based on TFC-1067, which would be great if true. AbbVie sponsored the clinical trial (!) that ended about 16 months ago. Product launch, milestones due and royalty might not be far away. They also elaboreted reasonable about royalty revenue that alone would be great. The pet diabetes deal on TFC-039 will probably be closed this year as well. I think this could provide significant value for the shareholders. Not only the terms and financial value, but also potential to bring in many new retail investors that love their cats - if the company manage to target this group of investors. We all know that the company want to start the clinical trial of anti-aging this autumn, which was reiterated in the interview. But it was the statement of corporate changes that provided confidence and gave the share price a boost. In order to finance the goals, the deal with AbbVie must be at least good enough. The management communicated that they understand what's neccessary to propel the company to the next level and up list on the exchange. Late this week the company put out a teaser for next week, more news to come! We can also expect a more detailed analysis by prcPartners. I started off this week pretty frustrated, since a positive reaction on the market just didn't happen, but ended the week with an insight that the company turn-around has just started. The volume is still good after a weeks trade. Now I expect that the share price to continue upwards. The first stop should be in the range 40-50 cents which is the former level hoovering for news. Depends on news/analysis next week. Very rough estimations for the rest of the year: * Pet deal 50-150 cents * Anti-aging clinical trial 50-150 cents * Corporate developments/news 50 cents A share price between 2 and 4 dollars might be in cards for this year. That's what I've been waiting for all these years. Not to mention the anti-aging deal that could be due next year... and up listing.

Turn-around Interesting week that provided the long awaited turn-around of the company - and the share price.  The non-disclosure of AbbVie deal details was painful and I noted that investors gave up and choose to sell. I don't blame them. Was the terms fantastic or in line with R+F to get street cred? Frustrating to say the least. The brief prc Partners analysis provided breadcrumbs that ignited some hope since they obviously know a bit more than other investors at this stage. The interview seems to be ready before the AbbVie deal was announced. The analyst claimed that AbbVie had already started product development based on TFC-1067, which would be great if true. AbbVie sponsored the clinical trial (!) that ended about 16 months ago. Product launch, milestones due and royalty might not be far away. They also elaboreted reasonable about royalty revenue that alone would be great. The pet diabetes deal on TFC-039 will probably be closed this year as well. I think this could provide significant value for the shareholders. Not only the terms and financial value, but also potential to bring in many new retail investors that love their cats - if the company manage to target this group of investors. We all know that the company want to start the clinical trial of anti-aging this autumn, which was reiterated in the interview. But it was the statement of corporate changes that provided confidence and gave the share price a boost. In order to finance the goals, the deal with AbbVie must be at least good enough. The management communicated that they understand what's neccessary to propel the company to the next level and up list on the exchange. Late this week the company put out a teaser for next week, more news to come! We can also expect a more detailed analysis by prcPartners. I started off this week pretty frustrated, since a positive reaction on the market just didn't happen, but ended the week with an insight that the company turn-around has just started. The volume is still good after a weeks trade. Now I expect that the share price to continue upwards. The first stop should be in the range 40-50 cents which is the former level hoovering for news. Depends on news/analysis next week. Very rough estimations for the rest of the year: * Pet deal 50-150 cents * Anti-aging clinical trial 50-150 cents * Corporate developments/news 50 cents A share price between 2 and 4 dollars might be in cards for this year. That's what I've been waiting for all these years. Not to mention the anti-aging deal that could be due next year... and up listing.